back to US directory
us clinical guidance

Giant cell arteritis

ACR/Vasculitis Foundation鈥揵ased emergency recognition, diagnostic confirmation, vascular imaging and glucocorticoid-sparing care for GCA.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults over age 50 with suspected or established giant cell arteritis involving cranial or large vessels. The ACR/Vasculitis Foundation guideline informs US diagnosis and management. Other vasculitides, isolated polymyalgia rheumatica and nonarteritic ischemic optic neuropathy require separate assessment.
sources for this section:ACR/VF GCA

The Bottom Line

  • Treat suspected vision-threatening GCA immediately; new visual symptoms, jaw claudication, ischemic neurologic features or a strongly compatible syndrome must not wait for biopsy or imaging.
  • ACR/VF conditionally recommends temporal artery biopsy over ultrasound for diagnosis in typical US practice, reflecting variable operator expertise, while imaging remains important when biopsy is negative or large-vessel disease is suspected.
  • Obtain a long-segment unilateral temporal artery biopsy, ideally within two weeks of starting glucocorticoids, recognizing that treatment should begin first when delay risks ischemia.
  • Use high-dose glucocorticoid therapy for active disease and consider tocilizumab with glucocorticoids to reduce relapse and steroid exposure, individualized for infection, monitoring, access and patient preference.
  • Perform noninvasive vascular imaging at diagnosis to assess large-vessel involvement and monitor known aortic or branch-vessel disease over time.
sources for this section:ACR/VF GCA

Practical clinical workflow

1
Ask specifically about new headache, scalp tenderness, jaw or tongue claudication, transient or permanent visual symptoms, constitutional illness, PMR symptoms and limb claudication; examine vision, pulses, bruits and temporal arteries.
2
Obtain ESR, CRP, blood count, metabolic and liver tests, but recognize normal markers do not completely exclude disease; involve ophthalmology immediately for visual symptoms.
3
Start appropriate glucocorticoid treatment without delay, arrange biopsy and vascular imaging through an urgent pathway and document baseline infection, bone and metabolic risk.
4
Confirm and phenotype disease with rheumatology, choose glucocorticoid-sparing therapy where appropriate and taper according to control rather than one universal duration.
5
Monitor relapse, medication toxicity, vision, limb ischemia and aortic disease; educate the patient to report recurrent ischemic symptoms immediately.
sources for this section:ACR/VF GCA

Safety boundaries and escalation

  • Transient or persistent visual loss is an emergency; same-day ophthalmology and rheumatology or emergency care is required even if symptoms resolve.
  • Stroke symptoms, tongue or scalp ischemia, aortic syndrome or critical limb ischemia requires emergency vascular and neurologic assessment.
  • High-dose glucocorticoids and tocilizumab can mask infection and inflammatory markers; use agent-specific screening and monitoring rather than relying on CRP alone.
  • A negative biopsy does not automatically exclude GCA when clinical probability is high; reassess specimen quality, alternative diagnosis and extracranial vascular imaging.
sources for this section:ACR/VF GCA

Localization

The ACR/VF preference for biopsy reflects US expertise assumptions and differs from ultrasound-first pathways in some countries. Local biopsy, vascular imaging and biologic access matter.
sources for this section:ACR/VF GCA

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Rheumatology and Vasculitis Foundation2021 ACR/VF Guideline for the Management of Giant Cell Arteritis and Takayasu ArteritisDOI 10.1002/art.41774 路 published 2021-07-08 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.